Health
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech
Georgetown researchers reported that combining BioXcel’s DPP inhibitor talabostat with a PD-1 blocker in mouse models of pancreatic…
When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…
Continue Reading
-
Noosa News24 hours agoThe Brisbane state school with an IB program preparing students for university
-
General23 hours agoThe ghost of Gough Whitlam is dead
-
General14 hours agoMillennials and Gen Z voters continued shift away from Coalition in 2025
-
General22 hours agoDonald Trump pardons Rudy Giuliani and others involved in trying to overturn 2020 election